Forvia

FRVIA

Equity

ISIN FR0000121147 / Valor 487591

Euronext - Euronext Paris (2024-09-16)

EUR 8.10-5.11%

Forvia
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Forvia is a company that specializes in the production and distribution of high-quality nutritional supplements for individuals with specific dietary needs, such as those with food allergies or sensitivities.

Summarized from source with an LLMView SourceSector: Consumer Cyclicals

Organic Sales Growth

Forvia reported an organic sales growth of 2.7% in the first half of 2024, outperforming the market by 290 basis points. This growth was achieved despite a broadly flat automotive production environment and unfavorable geographic and customer mix.

Operating Margin

Forvia's operating margin increased by 20 basis points year-on-year to 5.2% of sales in H1 2024. This improvement came despite a 30 basis points one-off impact from the Interiors North America operations.

Net Cash Flow

Forvia generated a solid net cash flow of €201 million in the first half of 2024, marking a 16.3% increase compared to H1 2023. This demonstrates the efficiency of the Group’s “Manage by Cash” program.

Order Intake

Forvia recorded a high order intake of €15 billion in the first half of 2024, with 40% of these orders coming from Asia. The company also strengthened its footprint in Asia through new joint ventures with Chinese manufacturers and the opening of a new plant in Thailand for BYD.

FY 2024 Guidance

Forvia confirmed its FY 2024 guidance, with sales and operating margin now expected to be in the lower end of the previously announced range. The company also reaffirmed its POWER25 key target of achieving a Net debt/Adjusted EBITDA ratio below 1.5 times by the end of 2025.

Summarized from source with an LLMView Source

Key figures

-60.7%1Y

-76.4%3Y

-80.8%5Y

Performance

47.1%1Y

55.0%3Y

52.7%5Y

Volatility